Compare Repligen Corporation Common Stock (RGEN) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Wells Fargo & Co — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Wells Fargo & Co trades at $81.4 (market cap $242.83B). The key difference: Wells Fargo & Co is far larger — about 21.8× Repligen Corporation Common Stock's market cap, and Wells Fargo & Co pays a 2.47% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Wells Fargo & Co for 88 Days on average.
| RGEN | WFC | |
|---|---|---|
Market Cap | $11.14B | $242.83B |
Volume | 1,259,263 | 21,447,763 |
Sector | Health | Financials |
52-Week High | $194.57 | $96.40 |
52-Week Low | $102.87 | $73.42 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $11.02B | $425.14B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Wells Fargo (WFC) trades at $80.74, down 3.07% today, with a bullish technical signal but mixed indicators. The stock shows strong profitability with a 25.97% net income margin and trades at a P/E of 11.74, below the industry average. Recent earnings beat expectations in two of the last three quarters, and a credit rating upgrade to 'A-' by S&P on October 1, 2026, reflects improved risk management.
The outlook is positive with a consensus price target of $98, implying 21% upside, supported by stable Fed stress tests and potential net interest income growth from rate hikes. Risks include volatile cash flows, with operating cash flow negative in 2025, and sensitivity to economic cycles. Institutional sentiment is balanced with 47% buy and hold ratings each.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
